BIOLASE Statistics
Total Valuation
BIOLASE has a market cap or net worth of $2.29 million. The enterprise value is $13.56 million.
| Market Cap | 2.29M |
| Enterprise Value | 13.56M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, after market close.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOLASE has 33.40 million shares outstanding. The number of shares has increased by 5,338.64% in one year.
| Shares Outstanding | 33.40M |
| Shares Change (YoY) | +5,338.64% |
| Shares Change (QoQ) | +488.65% |
| Owned by Insiders (%) | 0.33% |
| Owned by Institutions (%) | 8.97% |
| Float | 33.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.05 |
| Forward PS | 0.04 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.17
| Current Ratio | 1.17 |
| Quick Ratio | 0.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.98 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -61.91% |
| Return on Capital (ROIC) | -109.22% |
| Revenue Per Employee | $311,006 |
| Profits Per Employee | -$135,465 |
| Employee Count | 157 |
| Asset Turnover | 1.32 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, BIOLASE has paid $50,000 in taxes.
| Income Tax | 50,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.11% in the last 52 weeks. The beta is 0.72, so BIOLASE's price volatility has been lower than the market average.
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -99.11% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.64 |
| Relative Strength Index (RSI) | 37.26 |
| Average Volume (20 Days) | 501,574 |
Short Selling Information
The latest short interest is 2.10 million, so 6.28% of the outstanding shares have been sold short.
| Short Interest | 2.10M |
| Short Previous Month | 1.67M |
| Short % of Shares Out | 6.28% |
| Short % of Float | 6.31% |
| Short Ratio (days to cover) | 1.09 |
Income Statement
In the last 12 months, BIOLASE had revenue of $48.83 million and -$21.27 million in losses. Loss per share was -$14.94.
| Revenue | 48.83M |
| Gross Profit | 16.72M |
| Operating Income | -17.17M |
| Pretax Income | -21.22M |
| Net Income | -21.27M |
| EBITDA | -14.54M |
| EBIT | -17.85M |
| Loss Per Share | -$14.94 |
Balance Sheet
The company has $6.39 million in cash and $17.66 million in debt, giving a net cash position of -$11.26 million or -$0.34 per share.
| Cash & Cash Equivalents | 6.39M |
| Total Debt | 17.66M |
| Net Cash | -11.26M |
| Net Cash Per Share | -$0.34 |
| Equity (Book Value) | -1.93M |
| Book Value Per Share | -0.06 |
| Working Capital | 3.58M |
Cash Flow
In the last 12 months, operating cash flow was -$14.37 million and capital expenditures -$697,000, giving a free cash flow of -$15.07 million.
| Operating Cash Flow | -14.37M |
| Capital Expenditures | -697,000 |
| Free Cash Flow | -15.07M |
| FCF Per Share | -$0.84 |
Margins
Gross margin is 34.25%, with operating and profit margins of -35.17% and -43.56%.
| Gross Margin | 34.25% |
| Operating Margin | -35.17% |
| Pretax Margin | -43.45% |
| Profit Margin | -43.56% |
| EBITDA Margin | -29.78% |
| EBIT Margin | -36.56% |
| FCF Margin | -30.86% |
Dividends & Yields
BIOLASE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5,338.64% |
| Shareholder Yield | -5,338.64% |
| Earnings Yield | -927.02% |
| FCF Yield | -656.78% |
Analyst Forecast
The average price target for BIOLASE is $2.20, which is 3,102.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.20 |
| Price Target Difference | 3,102.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 28, 2023. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jul 28, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
BIOLASE has an Altman Z-Score of -13.31 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.31 |
| Piotroski F-Score | 4 |